Efficacy and safety of sublingual immunotherapy for peanut allergy: A systematic review and meta-analysis
Journal of Food Allergy · 01.07.2026 · 8 (1) · 22-30
DOI: 10.2500/jfa.2026.8.260001 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Food Allergy, erschienen am 01.07.2026. Verfasst von Isabella Christina Amaral de Lara und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Current management strategies for peanut allergy involve shared decision-making and several treatment modalities, including immunotherapy. Sublingual immunotherapy (SLIT) is emerging as a potential safer option for peanut immunotherapy.
Objective
We sought to systematically evaluate the efficacy and safety of SLIT for peanut allergy management in comparison with placebo.
Methods
We searched four data bases for randomized controlled trials (RCT). Outcomes of interest were tolerated dose during double-blind placebo controlled food challenge (DBPCFC), immunoglobulin E (IgE) and IgG4 levels, skin-prick test (SPT) and adverse events (AE).
Results
We identified three RCTs, comprising 108 patients with peanut allergy. There was a statistically significant increase in IgG4 levels (standardized mean difference [SMD] 0.56 kU/L [95% confidence interval [CI], 0.17-0.96 kU/L) and oropharyngeal AE (risk ratio [RR] 19.90 [95% CI, 4.00-99.07]) in the SLIT group. No significant difference in DBPCFC after treatment (mean difference [MD] 1612.90 mg [95% CI, −949.93 to 4175.74 mg]) and IgE levels (SMD −0.54 [95% CI, −1.46 to 0.37]) was observed. Respiratory, skin, and gastrointestinal AE incidences in the SLIT group were comparable with the placebo group (RR 2.11 [95% CI, 0.18-25.18], RR 1.57 [95% CI, 0.06-39.13], RR 3.51 [95% CI, 0.30-40.87], respectively). In children, SLIT showed improvement in DBPCFC results (MD 2529.57 mg [95% CI, 347.39-4711.75]) and SPT (MD −8.60 mm [95% CI, −11.13 to −6.07 mm).
Conclusion
Our meta-analysis demonstrated peanut SLIT safety and demonstrated a desensitization potential in children.
Zitieren
APA
Lara, I. C. A. D., Reis, M. R., Barbosa, A. B. D. A., Moraes, F. C. A. D., Neves, M. C. L. D. A., Dalmaschio, M. E. P., & Fernandes, L. R. (2026). Efficacy and safety of sublingual immunotherapy for peanut allergy: A systematic review and meta-analysis. Journal of Food Allergy, 8(1), 22-30. https://doi.org/10.2500/jfa.2026.8.260001
Vancouver
Lara ICAD, Reis MR, Barbosa ABDA, Moraes FCAD, Neves MCLDA, Dalmaschio MEP, et al. Efficacy and safety of sublingual immunotherapy for peanut allergy: A systematic review and meta-analysis. Journal of Food Allergy. 2026;8(1):22-30. doi:10.2500/jfa.2026.8.260001
BibTeX
@article{Lara2026,
author = {Lara, Isabella Christina Amaral de and Reis, Mariana Rachas and Barbosa, Alícia Batista de Almeida and Moraes, Francisco Cezar Aquino de and Neves, Maria Clara Leão de Andrade and Dalmaschio, Maria Eugenia Pedruzzi and Fernandes, Lilianne Rodrigues},
title = {Efficacy and safety of sublingual immunotherapy for peanut allergy: A systematic review and meta-analysis},
journal = {Journal of Food Allergy},
year = {2026},
volume = {8},
number = {1},
pages = {22--30},
doi = {10.2500/jfa.2026.8.260001}
}
EUVIMED